Drug resistance prediction for *Mycobacterium tuberculosis* with reference graphs

1.1 Author names

Michael B. Hall[1,2,*] (ORCiD: 0000-0003-3683-6208), Leandro Lima[1] (ORCiD: 0000-0001-8976-2762), Lachlan J. M. Coin[2] (ORCiD: 0000-0002-4300-455X), Zamin Iqbal[1,*] (ORCiD: 0000-0001-8466-7547)

1.2 Affiliation(s)

[1]European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridgeshire, United Kingdom
[2]Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Australia
[*]Corresponding authors

1.3 Corresponding author and email address

Michael B. Hall: michael.hall2 [at] unimelb.edu.au
Zamin Iqbal: zi [at] ebi.ac.uk

1.4 Keywords

genome graphs, reference graphs, drug resistance prediction, *Mycobacterium tuberculosis*, benchmark, software

2. Abstract

The dominant paradigm for analysing genetic variation relies on a central idea: all genomes in a species can be described as minor differences from a single reference genome. However, this approach can be problematic or inadequate for bacteria, where there can be significant sequence divergence within a species.

Reference graphs are an emerging solution to the reference bias issues implicit in the "single-reference" model. Such a graph represents variation at multiple scales within a population – e.g., nucleotide- and locus-level.

The genetic causes of drug resistance in bacteria have proven comparatively easy to decode compared with studies of human diseases. For example, it is possible to predict resistance to numerous anti-tuberculosis drugs by simply testing for the presence of a list of single nucleotide polymorphisms and insertion/deletions, commonly referred to as a catalogue.

We developed DrPRG (Drug resistance Prediction with Reference Graphs) using the bacterial reference graph method Pandora. First, we outline the construction of a *Mycobacterium tuberculosis* drug resistance reference graph, a process that can be replicated for other species. The graph is built from a global dataset of isolates with varying drug susceptibility profiles, thus capturing common and rare resistance- and susceptible-associated haplotypes.

We benchmark DrPRG against the existing graph-based tool Mykrobe and the pileup-based approach of TBProfiler using 44,709 and 138 publicly available Illumina and Nanopore datasets with associated phenotypes. We find DrPRG has significantly improved sensitivity and specificity for some drugs compared to these tools, with no significant decreases. It uses significantly less computational memory than both tools, and provides significantly faster runtimes, except when runtime is compared to Mykrobe on Illumina data.

We discover and discuss novel insights into resistance-conferring variation for *M. tuberculosis* - including deletion of genes *katG* and *pncA* – and suggest mutations that may warrant reclassification as associated with resistance.

3. Impact statement

Mycobacterium tuberculosis is the bacterium responsible for tuberculosis (TB). TB is one of the leading causes of death worldwide; before the coronavirus pandemic it was the leading cause of death from a single pathogen. Drug-resistant TB incidence has recently increased, making the detection of resistance even more vital. In this study, we develop a new software tool to predict drug resistance from whole-genome sequence data of the pathogen using new reference graph models to represent a reference genome. We evaluate it on *M. tuberculosis* against existing tools for resistance prediction and show improved performance. Using our method, we discover new resistance-associated variations and discuss reclassification of a selection of existing mutations. As such, this work contributes to TB drug resistance diagnostic efforts. In addition, the method could be applied to any bacterial species, so is of interest to anyone working on antimicrobial resistance.

4. Data summary

The authors confirm all supporting data, code and protocols have been provided within the article or through supplementary data files.
The software method presented in this work, DrPRG, is freely available from GitHub under an MIT license at https://github.com/mbhall88/drprg. We used commit 9492f25 for all results via a Singularity[1] container from the URI `docker://quay.io/mbhall88/drprg:9492f25`.
All code used to generate results for this study are available on GitHub at https://github.com/mbhall88/drprg-paper. All data used in this work are freely available from the SRA/ENA/DRA and a copy of the datasheet with all associated phenotype information can be downloaded from the archived repository at https://doi.org/10.5281/zenodo.7819984 or found in the previously mentioned GitHub repository.
The *Mycobacterium tuberculosis* index used in this work is available to download through DrPRG via the command `drprg index --download mtb@20230308` or from GitHub at https://github.com/mbhall88/drprg-index.

5. Introduction

Human industrialisation of antibiotic production and use over the last 100 years has led to a global rise in prevalence of antibiotic resistant bacterial strains. The phenomenon was even observed within patients in the first clinical trial of streptomycin as a drug for tuberculosis (TB) in 1948[2], and indeed as every new drug class has been introduced, so has resistance followed. Resistance mechanisms are varied, and can be caused by point mutations at key loci (e.g., binding sites of drugs[3,4]), frame-shifts rendering a gene non-functional[5], horizontal acquisition of new functionality via a new gene[6], or by up-regulation of efflux pumps to reduce the drug concentration within the cell[7].

Phenotypic and genotypic methods for detecting reduced susceptibility to drugs play complementary roles in clinical microbiology. Carefully defined phenotypic assays are used to give (semi)quantitative or binary measures of drug susceptibility; these have the benefit of

being experimental, quantitative measurements, and are able to detect resistance caused by hitherto unknown mechanisms. Prediction of drug resistance from genomic data has different advantages. Detection of a single nucleotide polymorphism (SNP) is arguably more consistent than a phenotypic assay, as it is not affected by whether the resistance it causes is near some threshold defining a resistant/susceptible boundary. Additionally, combining sequence datasets from different labs is more reliable than combining different phenotypic datasets, and using sequence data allows one to detect informative genetic changes (e.g., a tandem expansion of a single gene to form an array, thus increasing dosage). More subtly, defining the cut-off to separate resistant from susceptible is only simple when the minimum inhibitory concentration distribution is a simple bimodal distribution; in reality it is sometimes a convolution of multiple distributions caused by different mutations, and genetic data is sometimes needed to deconvolve the data and choose a threshold[8,9].

The key requirement for a genomic predictor is to have an encodable understanding of the genotype-to-phenotype map. Research has focussed on clinically important pathogens, primarily *Escherichia coli*, *Klebsiella pneumoniae*, *Salmonella enterica*, *Pseudomonas aeruginosa* and *Mycobacterium tuberculosis* (MTB). The challenges differ across species; almost all bacterial species are extremely diverse, with non-trivial pan-genomes and considerable horizontal gene transfer causing transmission of resistance genes[10]. In these cases, species are so diverse that detection of chromosomal SNPs is affected heavily by reference bias[11]. Furthermore, there is an appreciable proportion of resistance which is not currently explainable through known SNPs or genes [12–14]. At the other extreme, MTB has almost no accessory genome, and no recombination or plasmids[15]. Resistance appears to be caused entirely by mutations, indels, and rare structural variants, and simple sets of rules ("if any of these mutations are present, or any of these genes inactivated, the sample is resistant") work well for most drugs[16]. MTB has an exceptionally slow growth rate, meaning culture-based drug susceptibility testing (DST) is slow (2-4 weeks depending on media), and therefore sequencing is faster[17]. As part of the end TB strategy, the WHO strives towards universal access to DST[18], defining Target Product Profiles for molecular diagnostics[19,20] and publishing a catalogue of high-confidence resistance mutations intended to provide a basis for commercial diagnostics and future research[16]. There was a strong community-wide desire to integrate this catalogue into software for genotypic resistance prediction, although independent benchmarking confirmed there was still need for improvement[12]. Hence, there is a continuing need to improve the understanding of the genetic basis of resistance and integrate it into software for genotypic DST.

In this paper we develop and evaluate a new software tool for genotypic DST for MTB, built on a generic framework that can be used for any bacteria. Several tools have been developed previously[21–25]. Of these, only Mykrobe and TBProfiler work on Illumina and Nanopore data, and both have been heavily evaluated previously[22,23,26,27] - so we benchmark against these. Mykrobe uses de Bruijn graphs to encode known resistance alleles and thereby achieves high accuracy even on indel calls with Nanopore data[27]. However it is unable to detect novel alleles in known resistance genes, nor to detect gene truncation or deletion, which would be desirable. TBProfiler is based on mapping and variant calling (by default using Freebayes[28]), and detects gene deletions using Delly[29].

Our new software, called DrPRG (Drug resistance Prediction with Reference Graphs), builds on newer pan-genome technology than Mykrobe[11] using an independent graph for each gene in the catalogue, which makes it easier to go back-and-forth between VCF and the

graph. To build an index, it takes as input a catalogue of resistant variants (a simple 4-column TSV file), a file specifying expert rules (e.g. any missense variant between codons X and Y in gene Z causes resistance to drug W), and a VCF of population variation in the genes of interest. This allows it to easily incorporate the current WHO-endorsed catalogue[16], which is conservative, and for the user to update the catalogue or rules with minimal effort. Finally, to provide resistance predictions, it takes a prebuilt index (an MTB one is currently provided) and sequencing reads (FASTQ).

We describe the DrPRG method, and to evaluate it, gather the largest MTB dataset of sequencing data with associated phenotype information and reveal novel insights into resistance-determining mutations for this species.

6. Methods

DrPRG is a command-line software tool implemented in the Rust programming language. There are two main subcommands: `build` for building a reference graph and associated index files, and `predict` for producing genotypic resistance predictions from sequencing reads and an index (from `build`) .

6.1 Constructing a resistance-specific reference graph and index

The `build` subcommand of DrPRG requires a Variant Call Format (VCF) file of variants from which to build a reference graph, a catalogue of mutations that confer resistance or susceptibility for one or more drugs, and an annotation (GFF) and FASTA file of the reference genome.
For this work, we used the reference and annotation for the MTB strain H37Rv (accession NC_000962.3) and the default mutation catalogue from Mykrobe (v0.12.1)[12,26].
To ensure the reference graph is not biased towards a particular lineage or susceptibility profile, we selected samples from a VCF of 15,211 global MTB samples[30]. We randomly chose 20 samples from each lineage 1 through 4, as well as 20 samples from all other lineages combined. In addition, we included 17 clinical samples representing MTB global diversity (lineages 1-6)[31,32] to give a total of 117 samples. In the development phase of DrPRG we also found it necessary to add some common mutations not present in these 177 samples; as such, we added 48 mutations to the global VCF (these mutations are listed in archived repository – see Data summary). We did not add all catalogue mutations as there is a saturation point for mutation addition to a reference graph, and beyond this point, performance begins to decay[33].
The `build` subcommand turns this VCF into a reference graph by extracting a consensus sequence for each gene and sample. We use just those genes that occur in the mutation catalogue and include 100 bases flanking the gene. A multiple sequence alignment is constructed for each gene from these consensus sequences with MAFFT (v7.505)[34,35] and then a reference graph is constructed from these alignments with `make_prg` (v0.4.0)[11]. The final reference graph is then indexed with `pandora`[11].

6.2 Genotypic resistance prediction

Genotypic resistance prediction of a sample is performed by the `predict` subcommand of DrPRG. It takes an index produced by the `build` command (see Constructing a resistance-specific reference graph and index) and sequencing reads – Illumina or Nanopore are accepted. To generate predictions, DrPRG discovers novel variants (`pandora`), adds these to the reference graph (`make_prg` and MAFFT), and then genotypes the sample with respect

to this updated graph (`pandora`). The genotyped VCF is filtered such that we ignore any variant with less than 3 reads supporting it and require a minimum of 1% read depth on each strand. Next, each variant is compared to the catalogue. If an alternate allele has been called that corresponds with a catalogue variant, resistance ('R') is noted for the drug(s) associated with that mutation. If a variant in the VCF matches a catalogue mutation, but the genotype is null ('.'), we mark that mutation, and its associated drug(s), as failed ('F'). Where an alternate allele call does not match a mutation in the catalogue, we produce an unknown ('U') prediction for the drug(s) that have a known resistance-conferring mutation in the relevant gene.

DrPRG also has the capacity to detect minor alleles and call minor resistance ('r') or minor unknown ('u') in such cases. Minor alleles are called when a variant (that has passed the above filtering) is genotyped as being the susceptible (reference) allele, but there is also read depth on the resistant (alternate) allele above a given minor allele frequency parameter (`--maf`; default is 0.1 for Illumina data). Minor allele calling is turned off by default for Nanopore data as we found it led to a drastic increase in the number of false positive calls (this is also the case for Mykrobe and TBProfiler).

When building the index for DrPRG and making predictions, we also accept a file of "expert rules" for calling variants of a certain class. A rule is associated with a gene, an optional position range, a variant type, and the drug(s) that rule confers resistance to. Currently supported variant types are missense, nonsense, frameshift, and gene absence.

The output of running predict is a VCF file of all variants in the graph and a JSON file of resistance predictions for each drug in the index, along with the mutation(s) supporting that prediction and a unique identifier to find that variant in the VCF file (see Supplementary Section S1 for an example). The reference graph gene presence/absence (as determined by `pandora`) is also listed in the JSON file.

6.3 Benchmark

We compare the performance of DrPRG against Mykrobe (v0.12.1)[26] and TBProfiler (v4.3.0)[22] for MTB drug resistance prediction. Mykrobe is effectively a predecessor of DrPRG; it uses genome graphs, in the form of de Bruijn graphs, to construct a graph of all mutations in a catalogue and then genotypes the reads against this graph. TBProfiler is a more traditional approach which aligns reads to a single reference genome and calls variants from that alignment via a pileup.

A key part of such a benchmark is the catalogue of mutations, as this generally accounts for the majority of differences between tools[26]. As such, we use the same catalogue for all tools to ensure any differences are method-related - not catalogue disparities. The catalogue we chose is the default one provided in Mykrobe[12]. It is a combination of the catalogue described in Hunt *et al.* [26] and the category 1 and 2 mutation and expert rules from the 2021 WHO catalogue[16]. This catalogue contains mutations for 14 drugs: isoniazid, rifampicin, ethambutol, pyrazinamide, levofloxacin, moxifloxacin, ofloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, linezolid, and delamanid.

We used Mykrobe and TBProfiler with default parameters, except for a parameter in each indicating the sequencing technology of the data as Illumina or Nanopore and the TBProfiler option to not trim data (as we do this in Quality control).

We compare the prediction performance of each program using sensitivity and specificity. To calculate these metrics, we consider a true positive (TP) and true negative (TN) as a case where a program calls resistance and susceptible, respectively, and the phenotype agrees; a false positive (FP) as a resistant call by a program but a susceptible phenotype, with false

negatives (FN) being the inverse of FP. We only present results for drugs in the catalogue and where at least 10 samples had phenotypic data available.
To benchmark the runtime and memory usage of each tool, we used the Snakemake benchmark feature within our analysis pipeline[36].

6.4 Datasets

We gathered various MTB datasets where whole-genome sequencing data (Nanopore or Illumina) were available from public repositories (ENA/SRA/DRA) and associated phenotypes were accessible for at least one drug present in our catalogue[16,27,37–49].
All data was downloaded with `fastq-dl` (v1.1.1; https://github.com/rpetit3/fastq-dl).

6.5 Quality control

All downloaded Nanopore fastq files had adapters trimmed with `porechop` (v0.2.4; https://github.com/rrwick/Porechop), with the option to discard any reads with an adapter in the middle, and any reads with an average quality score below 7 were removed with `nanoq` (v0.9.0)[50]. Illumina reads were pre-processed with `fastp` (v0.23.2)[51] to remove adapter sequences, trim low quality bases from the ends of the reads, and remove duplicate reads and reads shorter than 30bp.
Sequencing reads were decontaminated as described in Hall *et al.*[27] and Walker *et al.*[16]. Briefly, sequenced reads were mapped to a database of common sputum contaminants and the MTB reference genome (H37Rv; accession NC_000962.3)[52] keeping only those reads where the best mapping was to H37Rv.
After quality control, we removed any sample with average read depth less than 15, or where more than 5% of the reads mapped to contaminants.
Lineage information was extracted from the TBProfiler results (see Benchmark).

6.6 Statistical Analysis

We used a Wilcoxon rank-sum paired data test from the Python library SciPy[53] to test for significant differences in runtime and memory usage between the three prediction tools.
The sensitivity and specificity confidence intervals were calculated with a Wilson's score interval with a coverage probability of 95%.

7. Results

To benchmark DrPRG, Mykrobe, and TBProfiler, we gathered an Illumina dataset of 45,702 MTB samples with a phenotype for at least one drug. After quality control (see Quality control), this number reduced to 44,709. In addition, we gathered 142 Nanopore samples, of which 138 passed quality control. In Figure 1 we show all available drug phenotypes for those interested in the dataset, yet our catalogue does not offer predictions for all drugs listed (see Benchmark). Lineage counts for all samples that passed quality control and have a single, major lineage call can be found in Table 1.



Figure 1: Drug phenotype counts for Illumina (upper) and Nanopore (lower) datasets. Bars are stratified and coloured by whether the phenotype is resistant (R; orange) or susceptible (S; green). Note, the y-axis is log-scaled. PAS=para-aminosalicylic acid

Table 1: Lineage counts from the Illumina and Nanopore datasets, covering main lineages 1-9 (L1-L9) and the three livestock-associated lineages (La1-La3) as defined in [54]

Lineage	Illumina	Nanopore
La1	239	0
La2	7	0
La3	71	0
L1	3907	32
L2	12870	38
L3	5803	9
L4	20731	59
L5	63	0
L6	78	0
L7	3	0
L9	1	0

7.1 Sensitivity and specificity performance

We present the sensitivity and specificity results for Illumina data in Figure 2 and Suppl. Table S1 and the Nanopore data in Figure 3 and Suppl. Table S2.

When comparing DrPRG's performance to that of Mykrobe and TBProfiler, we look for instances where the confidence intervals do not overlap; indicating a significant difference. With Illumina data (Figure 2 and Suppl. Table S1), DrPRG achieves significantly greater sensitivity than Mykrobe for rifampicin (96.4% [96.0-96.7] vs. 95.6% [95.2-95.9]), streptomycin (85.3% [84.4-86.3] vs. 83.1% [82.1-84.1]), amikacin (85.6% [83.9-87.1] vs. 80.8% [78.9-82.5]), capreomycin (77.5% [75.2-79.7] vs. 71.8% [69.3-74.1]), kanamycin (83.7% [82.1-85.2] vs. 79.9% [78.2-81.5]), and ethionamide (75.2% [73.7-76.8] vs. 71.4% [69.7-73.0]), with no significant difference for all other drugs. In terms of sensitivity, there was no significant difference between DrPRG and TBProfiler except for ethionamide, where DrPRG was significantly more sensitive (75.2% [73.7-76.8] vs. 71.5% [69.8-73.1]). For specificity, there was no significant difference between the tools except that DrPRG and Mykrobe were significantly better than TBProfiler for rifampicin (97.8% [97.6-98.0] vs. 97.2% [97.0-97.4]). There was no significant difference in sensitivity or specificity for any drug with Nanopore data.



Figure 2: Sensitivity (upper panel; y-axis) and specificity (lower panel; y-axis) of resistance predictions for different drugs (x-axis) from Illumina data. Error bars are coloured by prediction tool. The central horizontal line in each error bar is the sensitivity/specificity and the error bars represent the 95% confidence interval. Note, the sensitivity panel's y-axis is logit-scaled. This scale is similar to a log scale close to zero and to one (100%), and almost linear

around 0.5 (50%). The red dashed line in each panel represents the minimal standard WHO target product profile (TPP; where available) for next-generation drug susceptibility testing for sensitivity and specificity. INH=isoniazid, RIF=rifampicin, EMB=ethambutol, PZA=pyrazinamide, LFX=levofloxacin, MFX=moxifloxacin, OFX=ofloxacin, AMK=amikacin, CAP=capreomycin, KAN=kanamycin, STM=streptomycin, ETO=ethionamide, LZD=linezolid, DLM=delamanid.



Figure 3: Sensitivity (upper panel; y-axis) and specificity (lower panel; y-axis) of resistance predictions for different drugs (x-axis) from Nanopore data. Error bars are coloured by prediction tool. The central horizontal line in each error bar is the sensitivity/specificity and the error bars represent the 95% confidence interval. Note, the sensitivity panel's y-axis is logit-scaled. This scale is similar to a log scale close to zero and to one (100%), and almost linear around 0.5 (50%). The red dashed line in each panel represents the minimal standard WHO target product profile (TPP; where available) for next-generation drug susceptibility testing for sensitivity and specificity. INH=isoniazid, RIF=rifampicin, EMB=ethambutol, OFX=ofloxacin, AMK=amikacin, CAP=capreomycin, KAN=kanamycin, STM=streptomycin, ETO=ethionamide.

In both figures, we show the minimal requirements from the WHO target product profiles for sensitivity and specificity of genotypic drug susceptibility testing[19] as red dashed lines. Note, a sensitivity target is not specified by the WHO for ethambutol (EMB), capreomycin (CAP), kanamycin (KAN), streptomycin (STM), or ethionamide (ETO). For Illumina data, all tools' predictions for rifampicin, isoniazid, levofloxacin, moxifloxacin and amikacin are

above the sensitivity minimal requirement target. TBProfiler also exceeds the target for pyrazinamide, which DrPRG misses by 0.2%. No drug's sensitivity target was achieved with Nanopore data. For specificity, the tools are all very similar and either exceed or fall below the threshold together (see Figure 2). The target of >98% is met by all tools on Illumina data only for ofloxacin, amikacin, linezolid, and delamanid. Mykrobe also exceeds the target for capreomycin. As such, amikacin is the only drug where both sensitivity and specificity performance exceed the minimal requirement of the WHO target product profiles. Only capreomycin and kanamycin specificity targets are exceeded (by all tools) with Nanopore data.

However, for Illumina data, we did find that likely sample-swaps or phenotype instability[55] could lead to some drugs being on the threshold of the WHO target product profiles. If we excluded samples where all three tools make a FP call for the strong isoniazid and rifampicin resistance-conferring mutations *katG* S315T (*n*=152) and *rpoB* S450L (*n*=119) [16] respectively, all three tools would exceed the isoniazid specificity target of 98% - thus meeting both sensitivity and specificity targets for isoniazid. In addition, DrPRG and Mykrobe would meet the rifampicin specificity target of 98% – leading to both targets being met for rifampicin for these two tools. As previously reported [55,56], we also found a lot of instability in the ethambutol result caused by *embB* mutations M306I (*n*=827) and M306V (*n*=519) being called for phenotypically susceptible samples (FP) by all three tools. Other frequent consensus FP calls included: *fabG1* c-15t, which is associated with ethionamide (*n*=441) and isoniazid (*n*=241) resistance; *rrs* a1401g, which is associated with resistance to capreomycin (*n*=241), amikacin (*n*=70), and kanamycin (*n*=48). In addition there were common false positives from *gyrA* mutations A90V and D94G, which are associated with resistance to the fluoroquinolones levofloxacin (*n*=108 and *n*=70, respectively), moxifloxacin (*n*=419 and *n*=349) and ofloxacin (*n*=19 and *n*=17), and are known to cause heteroresistance and minimum inhibitory concentrations (MIC) close to the critical concentration threshold[57–59].

7.2 Evaluation of potential additions to the WHO catalogue

False negatives are much harder to investigate as it is not known which mutation(s) were missed as they are presumably not in the catalogue if all tools failed to make a call. However, looking through those FNs where DrPRG makes an "unknown" resistance call, we note some potential mutations that may need reclassification or inclusion in the WHO catalogue. For delamanid FNs, we found five different nonsense mutations in the *ddn* gene in seven samples – W20* (*n*=2), W27* (*n*=1), Q58* (*n*=1), W88* (*n*=2), and W139* (*n*=1) – none of which occurred in susceptible samples. We also found 13 pyrazinamide FN cases with a nonstop (stop-loss) mutation in *pncA* – this mutation type was also seen in two susceptible samples. Another *pncA* mutation, T100P, was also observed in 10 pyrazinamide FN samples and no susceptible samples. T100P only appears once in the WHO catalogue data ("solo" in a resistant sample). As such, it was given a grading of uncertain significance. As our dataset includes those samples in the WHO catalogue dataset, this means an additional nine isolates have been found with this mutation - indicating this may warrant an upgrade to 'associated with resistance'. We found an interesting case of allele combinations, where nine ethambutol FN samples have the same two *embA* mutation c-12a and c-11a and *embB* mutation P397T - this combination is only seen in two susceptible samples. Interestingly, *embB* P397T and *embA* c-12a don't appear in the WHO catalogue, but have been described as causing resistance previously[60]. Three *katG* mutations were also detected in isoniazid FN cases. First, G279D occurs in eight missed resistance samples and no susceptible cases. This mutation is graded as 'uncertain significance' in the WHO catalogue and was seen solo in

four resistant samples in that data. Singh *et al.* performed a protein structural analysis caused by this mutation and found it produced "an undesirable effect on the functionality of the protein"[61]. Second, G699E occurs in eight FN samples and no susceptible cases, but has a WHO grading of 'uncertain significance' based on six resistant isolates; thus, we add two extra samples to that count. And third, N138H occurs in 14 FN samples and one susceptible. In seven of these cases, it co-occurs with *ahpC* mutations t-75g (*n*=2) and t-76a (*n*=5). This mutation occurs in only three resistant isolates in the WHO catalogue dataset, giving it an uncertain significance, but we add a further 11 cases. This mutation has been found to cause a high isoniazid MIC and be associated with resistance[62,63].

7.3 Detection of large deletions

There are expert rules in the WHO catalogue which treat gene loss-of-function (any frameshift or nonsense mutation) in *katG*, *ethA*, *gid*, and *pncA* as causing resistance for isoniazid, ethionamide, streptomycin, and pyrazinamide, respectively[16]. Although examples of resistance caused by gene deletion are rare[64–68], with a dataset of this size (*n*=44,709), we can both evaluate these rules, and compare the detection power of DrPRG and TBProfiler for identifying gene deletions (Mykrobe does not, although in principle it could). In total we found 206 samples where DrPRG and/or TBProfiler identified deletions of *ethA*, *katG*, or *pncA*. Although many of these isolates did not have phenotype information for the associated drug (*n*=100), the results are nevertheless striking (Figure 4). Given the low false-positive rate of `pandora` for gene absence detection[11], these no-phenotype samples provide insight into how often gene deletions are occurring in clinical samples.

Of the 34 isolates where *katG* was identified as being absent, and an isoniazid phenotype was available, all 34 were phenotypically resistant. DrPRG detected all 34 (100% sensitivity) and TBProfiler identified 26 (76.5% sensitivity). Deletions of *pncA* were detected in 56 isolates, of which 49 were phenotypically resistant. DrPRG detected 47 (95.9% sensitivity) and TBProfiler detected 46 (93.9% sensitivity). Lastly, *ethA* was found to be missing in 16 samples with an ethionamide phenotype, of which 10 were phenotypically resistant. Both DrPRG and TBProfiler correctly predicted all 10 (100% sensitivity). No *gid* deletions were discovered. We note that the TP calls made by Mykrobe were due to it detecting large deletions that are present in the catalogue, which is understandable given the whole gene is deleted.

We conclude that DrPRG is slightly more sensitive at detecting large deletions than TBProfiler (and Mykrobe) for *katG*, and equivalent for *pncA* and *ethA*. However we note that the WHO expert rule which predicts resistance to isolates missing specific genes appears more accurate for *katG* (100% of isolates missing the gene are resistant) than for *pncA* (87% resistant) and *ethA* (62.5% resistant).



Figure 4: Impact of gene deletion on resistance classification. The title of each subplot indicates the gene and drug it effects. Bars are coloured by their classification and stratified by tool. Count (y-axis) indicates the number of gene deletions for that category. The NA bar (white with diagonal lines) indicates the number of samples with that gene deleted but no phenotype information for the respective drug. TP=true positive; FN=false negative; TN=true negative; FP=false positive; NA=no phenotype available.

7.4 Runtime and memory usage benchmark

The runtime and peak memory usage of each program was recorded for each sample and is presented in Figure 5. DrPRG (median 161 seconds) was significantly faster than both TBProfiler (307 seconds; $p \leq 0.0001$) and Mykrobe (230 seconds; $p \leq 0.0001$) on Illumina data. For Nanopore data, DrPRG (250 seconds) was significantly faster than TBProfiler (290 seconds; $p \leq 0.0001$), but significantly slower than Mykrobe (213 seconds; $p = 0.0347$). In terms of peak memory usage, DrPRG (Illumina median peak memory 58MB; Nanopore 277MB) used significantly less memory than Mykrobe (1538MB; 1538MB) and TBProfiler (1463MB; 1990MB) on both Illumina and Nanopore data ($p \leq 0.0001$ for all comparisons).



Figure 5: Benchmark of the maximum memory usage (left panels) and runtime (right panels) from Illumina (upper row) and Nanopore (lower row) data. Each point and violin is coloured by the tool, with each point representing a single sample. Statistical annotations are the result of a Wilcoxon rank-sum paired data test on each pair of tools. Dashed lines inside the violins represent the quartiles of the distribution. Note, the x-axis is log-scaled.

8. Discussion

In this work, we have presented a novel method for making drug resistance predictions with reference graphs. The method, DrPRG, requires only a reference genome and annotation, a catalogue of resistance-conferring mutations, a VCF of population variation from which to build a reference graph, and (optionally) a set of rules for types of variants in specific genes which cause resistance. We apply DrPRG to the pathogen *M. tuberculosis*, for which there is a great deal of information on the genotype/phenotype relationship, and a great need to provide good tools which implement and augment current and forthcoming versions of the WHO catalogue. We illustrate the performance of DrPRG against two existing methods for drug resistance prediction – Mykrobe and TBProfiler.

We benchmarked the methods on a high-quality Illumina sequencing dataset with associated phenotype profiles for 44,709 MTB genomes; the largest known dataset to-date[16]. All tools used the same catalogue and rules, and for most drugs, there was no significant difference between the tools. However, DrPRG did have a significantly higher specificity than TBProfiler for rifampicin predictions, and sensitivity for ethionamide predictions. DrPRG's sensitivity was also significantly greater than Mykrobe's for rifampicin, streptomycin, amikacin, capreomycin, kanamycin, and ethionamide. Evaluating detection of gene loss, we found DrPRG was more sensitive to *katG* deletions than TBProfiler.
We also benchmarked using 138 Nanopore-sequenced MTB samples with phenotype information, but found no significant difference between the tools. This Nanopore dataset was quite small and therefore the confidence intervals were large for all drugs. Increased Nanopore sequencing over time will provide better resolution of the overall sensitivity and specificity values and improve the methodological nuances of calling variants from this emerging, and continually changing, sequencing technology.

DrPRG also used significantly less memory than Mykrobe and TBProfiler on both Nanopore and Illumina data. In addition, the runtime of DrPRG was significant faster than both tools on Illumina data and faster than TBProfiler on Nanopore data. While the absolute values for memory and runtime for all tools mean they could all easily run on common computers found in the types of institutions likely to run them, the differences for the Nanopore data warrant noting. As Nanopore data can be generated "in the field", computational resource usage is critical. For example, in a recent collaboration of ours with the National Tuberculosis program in Madagascar[27], Nanopore sequencing and analysis are regularly performed on a laptop, meaning memory usage is sometimes a limiting factor. DrPRG's median peak memory was 277MB, meaning it can comfortably be run on any laptop and other mobile computing devices[69].

It is clear from the Illumina results that more work is needed to understand resistance-conferring mutations for delamanid and linezolid. However, we did find that nonsense mutations in the *ddn* gene appear likely to be resistance-conferring for delamanid – as has been noted previously[39,70–72]. We also found a novel (likely) mechanism of resistance to pyrazinamide - a nonstop mutation in *pncA*. Phenotype instability in *embB* at codon 306 was also found to be the main driver in poor ethambutol specificity, as has been noted elsewhere[55,56], indicating the need to further investigate cofactors that may influence the phenotype when mutations at this codon are present.

Gene absence/deletion detection allowed us to confirm that the absence of *katG* – a mechanism which is rare in clinical samples[64–67,73] - is highly likely to confer resistance to isoniazid. Additionally, we found that the absence of *pncA* is likely to cause resistance to pyrazinamide, as has been noted previously[68]. One finding that requires further investigation is the variability in ethionamide phenotype when *ethA* is absent. We found that only 63% of the samples with *ethA* missing, and an ethionamide phenotype, were resistant. An *et al.* have suggested that *ethA* deletion alone does not always cause resistance and there might be an alternate pathway via *mshA*[74].

Given the size of the Illumina dataset used in this work, the results provide a good marker of Illumina whole-genome sequencing's ability to replace traditional phenotyping methods. With the catalogue used in this study, DrPRG meets the WHO's target product profile for next-generation drug-susceptibility testing for both sensitivity and specificity for amikacin, and sensitivity only for rifampicin, isoniazid, levofloxacin, and moxifloxacin. However, if we exclude cases where all tools call *rpoB* S450L or *katG* S315T for phenotypically susceptible samples (these are strong markers of resistance[16] and therefore we suspect sample-swaps or phenotype error[75]), DrPRG also meets the specificity target product profile for rifampicin and isoniazid. For the other first-line drugs ethambutol and pyrazinamide, ethambutol does not have a WHO target and DrPRG's sensitivity is 0.2% below the WHO target (although the confidence interval spans the target), while the specificity target is missed by 0.8%.

The primary limitation of the DrPRG method relates to minor allele calls. DrPRG uses `pandora` for novel variant discovery, which combines a graph of known population variants (which can be detected at low frequency) with *de novo* detection of other variants if present at above ~50% frequency. Thus, it can miss minor allele calls if the allele is absent from its reference graph. While this issue did not impact most drugs, it did account for the majority of cases where DrPRG missed pyrazinamide-resistant calls (in *pncA*), but the other tools correctly called resistance. Unlike most other genes, where there are a relatively small number of resistance-conferring mutations, or they're localised to a specific region (e.g. the rifampicin-resistance determining region in *rpoB*), resistance-conferring mutations are numerous - with most being rare - and distributed throughout *pncA*[16,76,77]. Adding all of these mutations will, and does, lead to decreased performance of the reference graph[33], and

so improving minor allele calling for pyrazinamide remains a challenge we need to revisit in the future.
One final limitation is the small number of Nanopore-sequenced MTB isolates with phenotypic information. In order to get a clearer picture of the sensitivities and specificities this sequencing technology can provide, we need much larger and more diverse data.

In conclusion, DrPRG is a fast, memory frugal software program that can be applied to any bacterial species. We showed that on MTB, it performs as well as, or better than two other commonly used tools for resistance prediction. We also collected and curated the largest dataset of MTB Illumina-sequenced genomes with phenotype information and hope this will benefit future work to improved genotypic drug susceptibility testing for this species. While we applied DrPRG to MTB in this study, it is a framework that is agnostic to the species. MTB is likely one of the bacterial species with the least to gain from reference graphs given its relatively conserved (closed) pan-genome compared to other common species[78]. As such, we expect the benefits and performance of DrPRG to improve as the openness of the species' pan-genome increases[11]; especially given its good performance on a reasonably closed pan-genome.

9. Author statements

9.1 Author contributions

M.B.H: conceptualisation, data curation, formal analysis, investigation, methodology, resources, software, visualisation, writing – original draft, writing – review & editing. L.L: resources, software, writing – review & editing. L.J.M.C: funding acquisition, methodology, supervision, writing – review & editing. Z.I: conceptualisation, funding acquisition, methodology, supervision, writing – original draft, writing – review & editing.

9.2 Conflicts of interest

The authors declare no conflicts of interest.

9.3 Funding information

M.B.H. and L.J.M.C were supported by an Australian Government Medical Research Future Fund (MRFF) grant (2020/MRF1200856).

9.4 Acknowledgements

We thank Kerri M. Malone for sharing her MTB knowledge through many discussions and critiquing the final manuscript. We also thank Martin Hunt and Jeff Knaggs for facilitating access to the CRyPTIC VCFs. Finally, we would like to acknowledge Timothy Walker for his clinically-relevant MTB advice.

10. References

1. Kurtzer GM, Sochat V, Bauer MW. Singularity: Scientific containers for mobility of compute. PLOS ONE. 2017;12: e0177459. doi:10.1371/journal.pone.0177459

2. Medical Research Council. Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation. Br Med J. 1948;2: 769–782. doi:10.1136/bmj.2.4582.769

530 3. Wengenack NL, Todorovic S, Yu L, Rusnak F. Evidence for Differential Binding of
531 Isoniazid by Mycobacterium tuberculosis KatG and the Isoniazid-Resistant Mutant
532 KatG(S315T). Biochemistry. 1998;37: 15825–15834. doi:10.1021/bi982023k

533 4. Hackbarth CJ, Kocagoz T, Kocagoz S, Chambers HF. Point mutations in Staphylococcus
534 aureus PBP 2 gene affect penicillin-binding kinetics and are associated with resistance.
535 Antimicrob Agents Chemother. 1995;39: 103–106. doi:10.1128/AAC.39.1.103

536 5. Esposito EP, Cervoni M, Bernardo M, Crivaro V, Cuccurullo S, Imperi F, et al. Molecular
537 Epidemiology and Virulence Profiles of Colistin-Resistant Klebsiella pneumoniae Blood
538 Isolates From the Hospital Agency "Ospedale dei Colli," Naples, Italy. Front Microbiol.
539 2018;9. doi:10.3389/fmicb.2018.01463

540 6. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. Emergence of plasmid-
541 mediated colistin resistance mechanism MCR-1 in animals and human beings in China:
542 a microbiological and molecular biological study. Lancet Infect Dis. 2016;16: 161–168.
543 doi:10.1016/S1473-3099(15)00424-7

544 7. Maira-Litrán T, Allison DG, Gilbert P. An evaluation of the potential of the multiple
545 antibiotic resistance operon (mar) and the multidrug efflux pump acrAB to moderate
546 resistance towards ciprofloxacin in Escherichia coli biofilms. J Antimicrob Chemother.
547 2000;45: 789–795. doi:10.1093/jac/45.6.789

548 8. Werngren J, Sturegård E, Juréen P, Ängeby K, Hoffner S, Schön T. Reevaluation of the
549 Critical Concentration for Drug Susceptibility Testing of Mycobacterium tuberculosis
550 against Pyrazinamide Using Wild-Type MIC Distributions and pncA Gene Sequencing.
551 Antimicrob Agents Chemother. 2012;56: 1253–1257. doi:10.1128/AAC.05894-11

552 9. Schön T, Miotto P, Köser CU, Viveiros M, Böttger E, Cambau E. Mycobacterium
553 tuberculosis drug-resistance testing: challenges, recent developments and perspectives.
554 Clin Microbiol Infect. 2017;23: 154–160. doi:10.1016/j.cmi.2016.10.022

555 10. McInerney JO, McNally A, O'Connell MJ. Why prokaryotes have pangenomes. Nat
556 Microbiol. 2017;2: 17040. doi:10.1038/nmicrobiol.2017.40

557 11. Colquhoun RM, Hall MB, Lima L, Roberts LW, Malone KM, Hunt M, et al. Pandora:
558 nucleotide-resolution bacterial pan-genomics with reference graphs. Genome Biol.
559 2021;22: 267. doi:10.1186/s13059-021-02473-1

560 12. Hall MB, Coin LJM. Assessment of the 2021 WHO Mycobacterium tuberculosis drug
561 resistance mutation catalogue on an independent dataset. Lancet Microbe. 2022.
562 doi:10.1016/s2666-5247(22)00151-3

563 13. Mahfouz N, Ferreira I, Beisken S, von Haeseler A, Posch AE. Large-scale assessment of
564 antimicrobial resistance marker databases for genetic phenotype prediction: a systematic
565 review. J Antimicrob Chemother. 2020;75: 3099–3108. doi:10.1093/jac/dkaa257

566 14. Hendriksen RS, Bortolaia V, Tate H, Tyson GH, Aarestrup FM, McDermott PF. Using
567 Genomics to Track Global Antimicrobial Resistance. Front Public Health. 2019;7.
568 doi:10.3389/fpubh.2019.00242

15. Godfroid M, Dagan T, Kupczok A. Recombination Signal in Mycobacterium tuberculosis Stems from Reference-guided Assemblies and Alignment Artefacts. Genome Biol Evol. 2018;10: 1920–1926. doi:10.1093/gbe/evy143

16. Walker TM, Miotto P, Köser CU, Fowler PW, Knaggs J, Iqbal Z, et al. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis. Lancet Microbe. 2022. doi:10.1016/s2666-5247(21)00301-3

17. Votintseva AA, Bradley P, Pankhurst L, Elias C del O, Loose M, Nilgiriwala K, et al. Same-Day Diagnostic and Surveillance Data for Tuberculosis via Whole-Genome Sequencing of Direct Respiratory Samples. J Clin Microbiol. 2017;55: 1285–1298. doi:10.1128/jcm.02483-16

18. The end TB strategy. Geneva: World Health Organization; 2015. Report No.: WHO/HTM/TB/2015.19. Available: https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19

19. Target product profile for next-generation drug-susceptibility testing at peripheral centres. Geneva: World Health Organization; 2021. Available: https://www.who.int/publications/i/item/9789240032361

20. MacLean EL-H, Miotto P, Angulo LG, Chiacchiaretta M, Walker TM, Casenghi M, et al. Updating the WHO target product profile for next-generation Mycobacterium tuberculosis drug susceptibility testing at peripheral centres. PLOS Glob Public Health. 2023;3: e0001754. doi:10.1371/journal.pgph.0001754

21. Steiner A, Stucki D, Coscolla M, Borrell S, Gagneux S. KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes. BMC Genomics. 2014;15: 881. doi:10.1186/1471-2164-15-881

22. Phelan JE, O'Sullivan DM, Machado D, Ramos J, Oppong YEA, Campino S, et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019;11: 41. doi:10.1186/s13073-019-0650-x

23. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, et al. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun. 2015;6: 10063. doi:10.1038/ncomms10063

24. Kohl TA, Utpatel C, Schleusener V, Filippo MRD, Beckert P, Cirillo DM, et al. MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. PeerJ. 2018;6: e5895. doi:10.7717/peerj.5895

25. Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, et al. PhyResSE: a Web Tool Delineating Mycobacterium tuberculosis Antibiotic Resistance and Lineage from Whole-Genome Sequencing Data. J Clin Microbiol. 2015;53: 1908–1914. doi:10.1128/JCM.00025-15

607 26. Hunt M, Bradley P, Lapierre SG, Heys S, Thomsit M, Hall MB, et al. Antibiotic
608 resistance prediction for Mycobacterium tuberculosis from genome sequence data with
609 Mykrobe. Wellcome Open Res. 2019;4: 191. doi:10.12688/wellcomeopenres.15603.1

610 27. Hall MB, Rabodoarivelo MS, Koch A, Dippenaar A, George S, Grobbelaar M, et al.
611 Evaluation of Nanopore sequencing for Mycobacterium tuberculosis drug susceptibility
612 testing and outbreak investigation: a genomic analysis. Lancet Microbe. 2022;0.
613 doi:10.1016/S2666-5247(22)00301-9

614 28. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing.
615 arXiv; 2012. doi:10.48550/arXiv.1207.3907

616 29. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural
617 variant discovery by integrated paired-end and split-read analysis. Bioinformatics.
618 2012;28: i333–i339. doi:10.1093/bioinformatics/bts378

619 30. The CRyPTIC Consortium and the 100,000 Genomes Project. A data compendium
620 associating the genomes of 12,289 Mycobacterium tuberculosis isolates with
621 quantitative resistance phenotypes to 13 antibiotics. PLOS Biol. 2022;20: e3001721.
622 doi:10.1371/journal.pbio.3001721

623 31. Chiner-Oms Á, Berney M, Boinett C, González-Candelas F, Young DB, Gagneux S, et al.
624 Genome-wide mutational biases fuel transcriptional diversity in the Mycobacterium
625 tuberculosis complex. Nat Commun. 2019;10: 3994. doi:10.1038/s41467-019-11948-6

626 32. Letcher B, Hunt M, Iqbal Z. Gramtools enables multiscale variation analysis with
627 genome graphs. Genome Biol. 2021;22: 259. doi:10.1186/s13059-021-02474-0

628 33. Pritt J, Chen N-C, Langmead B. FORGe: prioritizing variants for graph genomes.
629 Genome Biol. 2018;19: 220. doi:10.1186/s13059-018-1595-x

630 34. Katoh K, Frith MC. Adding unaligned sequences into an existing alignment using
631 MAFFT and LAST. Bioinformatics. 2012;28: 3144–3146.
632 doi:10.1093/bioinformatics/bts578

633 35. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple
634 sequence alignment based on fast Fourier transform. Nucleic Acids Res. 2002;30: 3059–
635 3066. doi:10.1093/nar/gkf436

636 36. Mölder F, Jablonski KP, Letcher B, Hall MB, Tomkins-Tinch CH, Sochat V, et al.
637 Sustainable data analysis with Snakemake. F1000Research. 2021;10: 33.
638 doi:10.12688/f1000research.29032.2

639 37. Gröschel MI, Owens M, Freschi L, Vargas R, Marin MG, Phelan J, et al. GenTB: A user-
640 friendly genome-based predictor for tuberculosis resistance powered by machine
641 learning. Genome Med. 2021;13: 138. doi:10.1186/s13073-021-00953-4

642 38. Trisakul K, Nonghanphithak D, Chaiyachat P, Kaewprasert O, Sakmongkoljit K,
643 Reechaipichitkul W, et al. High clustering rate and genotypic drug-susceptibility
644 screening for the newly recommended anti-tuberculosis drugs among global extensively

645 drug-resistant Mycobacterium tuberculosis isolates. Emerg Microbes Infect. 2022;11:
646 1857–1866. doi:10.1080/22221751.2022.2099304

647 39. Battaglia S, Spitaleri A, Cabibbe AM, Meehan CJ, Utpatel C, Ismail N, et al.
648 Characterization of Genomic Variants Associated with Resistance to Bedaquiline and
649 Delamanid in Naive Mycobacterium tuberculosis Clinical Strains. J Clin Microbiol.
650 2020;58. doi:10.1128/jcm.01304-20

651 40. Huang H, Ding N, Yang T, Li C, Jia X, Wang G, et al. Cross-sectional Whole-genome
652 Sequencing and Epidemiological Study of Multidrug-resistant Mycobacterium
653 tuberculosis in China. Clin Infect Dis Off Publ Infect Dis Soc Am. 2019;69: 405–413.
654 doi:10.1093/cid/ciy883

655 41. Bainomugisa A, Lavu E, Hiashiri S, Majumdar S, Honjepari A, Moke R, et al. Multi-
656 clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium
657 tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades.
658 Microb Genomics. 2018;4: e000147. doi:10.1099/mgen.0.000147

659 42. Smith C, Halse TA, Shea J, Modestil H, Fowler RC, Musser KA, et al. Assessing
660 Nanopore sequencing for clinical diagnostics: A comparison of NGS methods for
661 Mycobacterium tuberculosis. J Clin Microbiol. 2020. doi:10.1128/jcm.00583-20

662 43. Peker N, Schuele L, Kok N, Terrazos M, Neuenschwander SM, Beer J de, et al.
663 Evaluation of whole-genome sequence data analysis approaches for short- and long-read
664 sequencing of Mycobacterium tuberculosis. Microb Genomics. 2021;7.
665 doi:10.1099/mgen.0.000695

666 44. Merker M, Rasigade J-P, Barbier M, Cox H, Feuerriegel S, Kohl TA, et al.
667 Transcontinental spread and evolution of Mycobacterium tuberculosis W148
668 European/Russian clade toward extensively drug resistant tuberculosis. Nat Commun.
669 2022;13: 5105. doi:10.1038/s41467-022-32455-1

670 45. Finci I, Albertini A, Merker M, Andres S, Bablishvili N, Barilar I, et al. Investigating
671 resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and
672 phenotypic antimicrobial susceptibility testing: a multicentre observational study.
673 Lancet Microbe. 2022;3: e672–e682. doi:10.1016/s2666-5247(22)00116-1

674 46. Roberts LW, Malone KM, Hunt M, Joseph L, Wintringer P, Knaggs J, et al. Repeated
675 evolution of bedaquiline resistance in Mycobacterium tuberculosis is driven by
676 truncation of mmpR5. bioRxiv; 2022. p. 2022.12.08.519610.
677 doi:10.1101/2022.12.08.519610

678 47. Di Marco F, Spitaleri A, Battaglia S, Batignani V, Cabibbe AM, Cirillo DM. Advantages
679 of long- and short-reads sequencing for the hybrid investigation of the Mycobacterium
680 tuberculosis genome. Front Microbiol. 2023;14. doi:10.3389/fmicb.2023.1104456

681 48. Lempens P, Decroo T, Aung KJM, Hossain MA, Rigouts L, Meehan CJ, et al. Initial
682 resistance to companion drugs should not be considered an exclusion criterion for the
683 shorter multidrug-resistant tuberculosis treatment regimen. Int J Infect Dis. 2020;100:
684 357–365. doi:10.1016/j.ijid.2020.08.042

685 49. Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A, et al.
686 Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by
687 high-confidence resistance-conferring mutations. Sci Rep. 2018;8: 3246.
688 doi:10.1038/s41598-018-21378-x

689 50. Steinig E, Coin L. Nanoq: ultra-fast quality control for nanopore reads. J Open Source
690 Softw. 2022;7: 2991. doi:10.21105/joss.02991

691 51. Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor.
692 Bioinformatics. 2018;34: i884–i890. doi:10.1093/bioinformatics/bty560

693 52. Hunt M, Letcher B, Malone KM, Nguyen G, Hall MB, Colquhoun RM, et al. Minos:
694 variant adjudication and joint genotyping of cohorts of bacterial genomes. Genome Biol.
695 2022;23: 147. doi:10.1186/s13059-022-02714-x

696 53. Virtanen P, Gommers R, Oliphant TE, Haberland M, Reddy T, Cournapeau D, et al. SciPy
697 1.0: fundamental algorithms for scientific computing in Python. Nat Methods. 2020;17:
698 261–272. doi:10.1038/s41592-019-0686-2

699 54. Zwyer M, avusoglu C, Ghielmetti G, Pacciarini M, Scaltriti E, Van Soolingen D, et al. A
700 new nomenclature for the livestock-associated Mycobacterium tuberculosis complex
701 based on phylogenomics. Open Res Eur. 2021;1. doi:10.12688/openreseurope.14029.2

702 55. Chen Y, Takiff HE, Gao Q. Phenotypic instability of Mycobacterium tuberculosis strains
703 harbouring clinically prevalent drug-resistant mutations. Lancet Microbe. 2023;0.
704 doi:10.1016/S2666-5247(23)00007-1

705 56. Sirgel FA, Warren RM, Streicher EM, Victor TC, Helden PD van, Böttger EC. embB306
706 Mutations as Molecular Indicators to Predict Ethambutol Susceptibility in
707 Mycobacterium tuberculosis. Chemotherapy. 2013;58: 358–363.
708 doi:10.1159/000343474

709 57. Huo F, Ma Y, Li S, Xue Y, Shang Y, Dong L, et al. Specific gyrA Gene Mutations
710 Correlate with High Prevalence of Discordant Levofloxacin Resistance in
711 Mycobacterium tuberculosis Isolates from Beijing, China. J Mol Diagn. 2020;22: 1199–
712 1204. doi:10.1016/j.jmoldx.2020.06.010

713 58. Brankin AE, Fowler PW. Inclusion of minor alleles improves catalogue-based prediction
714 of fluoroquinolone resistance in Mycobacterium tuberculosis. JAC-Antimicrob Resist.
715 2023;5: dlad039. doi:10.1093/jacamr/dlad039

716 59. Nimmo C, Brien K, Millard J, Grant AD, Padayatchi N, Pym AS, et al. Dynamics of
717 within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment.
718 EBioMedicine. 2020;55: 102747. doi:10.1016/j.ebiom.2020.102747

719 60. Perdigão J, Gomes P, Miranda A, Maltez F, Machado D, Silva C, et al. Using genomics to
720 understand the origin and dispersion of multidrug and extensively drug resistant
721 tuberculosis in Portugal. Sci Rep. 2020;10: 2600. doi:10.1038/s41598-020-59558-3

722 61. Singh A, Singh A, Grover S, Pandey B, Kumari A, Grover A. Wild-type catalase
723 peroxidase vs G279D mutant type: Molecular basis of Isoniazid drug resistance in

724 Mycobacterium tuberculosis. Gene. 2018;641: 226–234.
725 doi:10.1016/j.gene.2017.10.047

726 62. Vaziri F, Kohl TA, Ghajavand H, Kargarpour Kamakoli M, Merker M, Hadifar S, et al.
727 Genetic Diversity of Multi- and Extensively Drug-Resistant Mycobacterium
728 tuberculosis Isolates in the Capital of Iran, Revealed by Whole-Genome Sequencing. J
729 Clin Microbiol. 2019;57: e01477-18. doi:10.1128/JCM.01477-18

730 63. de Lourdes do Carmo Guimarães Diniz J, von Groll A, Unis G, Dalla-Costa ER, Rosa
731 Rossetti ML, Vianna JS, et al. Whole-genome sequencing as a tool for studying the
732 microevolution of drug-resistant serial Mycobacterium tuberculosis isolates.
733 Tuberculosis. 2021;131: 102137. doi:10.1016/j.tube.2021.102137

734 64. Altamirano M, Marostenmaki J, Wong A, FitzGerald M, Black WA, Smith JA. Mutations
735 in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis
736 isolates. J Infect Dis. 1994;169: 1162–1165. doi:10.1093/infdis/169.5.1162

737 65. Ferrazoli L, Palaci M, da Silva Telles MA, Ueki SY, Kritski A, Marques LRM, et al.
738 Catalase Expression, katG, And MIC Of Isoniazid For Mycobacterium tuberculosis
739 Isolates From SãO Paulo, Brazil. J Infect Dis. 1995;171: 237–240.
740 doi:10.1093/infdis/171.1.237

741 66. Ramaswamy SV, Reich R, Dou S-J, Jasperse L, Pan X, Wanger A, et al. Single
742 Nucleotide Polymorphisms in Genes Associated with Isoniazid Resistance in
743 Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2003;47: 1241–1250.
744 doi:10.1128/AAC.47.4.1241-1250.2003

745 67. Zhang Y, Heym B, Allen B, Young D, Cole S. The catalase—peroxidase gene and
746 isoniazid resistance of Mycobacterium tuberculosis. Nature. 1992;358: 591–593.
747 doi:10.1038/358591a0

748 68. Martinez E, Holmes N, Jelfs P, Sintchenko V. Genome sequencing reveals novel deletions
749 associated with secondary resistance to pyrazinamide in MDR Mycobacterium
750 tuberculosis. J Antimicrob Chemother. 2015;70: 2511–2514. doi:10.1093/jac/dkv128

751 69. Samarakoon H, Punchihewa S, Senanayake A, Hammond JM, Stevanovski I, Ferguson
752 JM, et al. Genopo: a nanopore sequencing analysis toolkit for portable Android devices.
753 Commun Biol. 2020;3: 1–5. doi:10.1038/s42003-020-01270-z

754 70. Gómez-González PJ, Perdigao J, Gomes P, Puyen ZM, Santos-Lazaro D, Napier G, et al.
755 Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to
756 bedaquiline, delamanid and pretomanid. Sci Rep. 2021;11: 19431. doi:10.1038/s41598-
757 021-98862-4

758 71. Schena E, Nedialkova L, Borroni E, Battaglia S, Cabibbe AM, Niemann S, et al.
759 Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin
760 microtitre assay and the BACTEC™ MGIT™ 960 system. J Antimicrob Chemother.
761 2016;71: 1532–1539. doi:10.1093/jac/dkw044

762 72. Gomes LC, Campino S, Marinho CRF, Clark TG, Phelan JE. Whole genome sequencing
763 reveals large deletions and other loss of function mutations in Mycobacterium

764 tuberculosis drug resistance genes. Microb Genomics. 2021;7: 000724.
765 doi:10.1099/mgen.0.000724

766 73. De Maio F, Cingolani A, Bianco DM, Salustri A, Palucci I, Sanguinetti M, et al. First
767 description of the katG gene deletion in a Mycobacterium tuberculosis clinical isolate
768 and its impact on the mycobacterial fitness. Int J Med Microbiol. 2021;311: 151506.
769 doi:10.1016/j.ijmm.2021.151506

770 74. Ang MLT, Zainul Rahim SZ, de Sessions PF, Lin W, Koh V, Pethe K, et al. EthA/R-
771 Independent Killing of Mycobacterium tuberculosis by Ethionamide. Front Microbiol.
772 2017;8. doi:10.3389/fmicb.2017.00710

773 75. The CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of Susceptibility
774 to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med. 2018;379: 1403–
775 1415. doi:10.1056/NEJMoa1800474

776 76. Köser CU, Cirillo DM, Miotto P. How To Optimally Combine Genotypic and Phenotypic
777 Drug Susceptibility Testing Methods for Pyrazinamide. Antimicrob Agents Chemother.
778 2020;64: e01003-20. doi:10.1128/AAC.01003-20

779 77. Yadon AN, Maharaj K, Adamson JH, Lai Y-P, Sacchettini JC, Ioerger TR, et al. A
780 comprehensive characterization of PncA polymorphisms that confer resistance to
781 pyrazinamide. Nat Commun. 2017;8: 588. doi:10.1038/s41467-017-00721-2

782 78. Park S-C, Lee K, Kim YO, Won S, Chun J. Large-Scale Genomics Reveals the Genetic
783 Characteristics of Seven Species and Importance of Phylogenetic Distance for
784 Estimating Pan-Genome Size. Front Microbiol. 2019;10. doi:10.3389/fmicb.2019.00834

785